ArticleAnalytical and bioanalytical chemistry2026
Diagnosis of gout using monosodium urate (MSU) crystal binding peptides screened from Fv-antibody library.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nucleotide Metabolism in Health and Disease.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The diagnosis of gout was developed through the detection of monosodium urate (MSU) crystals in the synovial fluid of patients with gout using MSU-binding peptides. Amino acid sequences with a high binding affinity to MSU crystals were screened from the Fv-antibody library using MSU crystals as probes. Five CDR3 sequences were successfully screened as MSU-binding sequences from the Fv-antibody library, and these were synthesized into 11-residue peptides. Among these, two MSU-binding peptides (Nos. 1 and 3) showed a significantly higher affinity for preventing the growth of MSU crystals. A detection kit for MSU crystals was developed using MSU-binding peptide No. 3 (biotin-labeled). An assay was performed using samples from patients with gout (n = 23) and healthy controls (n = 29). The sensitivity and specificity of this assay were estimated to be 82.6% and 93.1%, respectively, at a confidence interval of 95%. These results show that the MSU crystal assay based on MSU-binding peptides can be effectively applied for the medical diagnosis of gout. Furthermore, the MSU crystal assay can be carried out using only reagents, without polarized microscopes or trained medical doctors.
Indexed as
Identifiers
41428213What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.